Fosmanogepix for the Treatment of Invasive Mold Diseases Caused by <i>Aspergillus</i> Species and Rare Molds: A Phase 2, Open-Label Study (AEGIS)
Safety profile was acceptable in high-risk patients with limited treatment options, supporting development of FMGX for treating IMDs caused by Aspergillus and rare molds. Clinical Trials Registration. NCT04240886; EudraCT number: 2019-001386-33.
Authors
- Rienk Pypstra
- Michael R. Hodges (ORCID: https://orcid.org/0009-0003-3052-2344)
- Monica A. Slavin (ORCID: https://orcid.org/0000-0002-8443-314X)
- Sanjeet Dadwal (ORCID: https://orcid.org/0000-0002-1099-0568)
- Galia Rahav (ORCID: https://orcid.org/0000-0003-4039-0958)
- Susan Hazel (ORCID: https://orcid.org/0000-0002-1804-690X)
- George R. Thompson (ORCID: https://orcid.org/0000-0001-8518-5750)
- Oliver A. Cornely (ORCID: https://orcid.org/0000-0001-9599-3137)
- Margaret Tawadrous (ORCID: https://orcid.org/0000-0002-6815-2647)
- Abhijeet Jakate (ORCID: https://orcid.org/0009-0000-2196-5782)
- Johan A. Maertens (ORCID: https://orcid.org/0000-0003-4257-5980)
- Mary Almas (ORCID: https://orcid.org/0009-0003-1077-7307)
Institutions
- City Of Hope National Medical Center (US)
- Pfizer (United States) (US)
- University of Cologne (DE)
- Rega Institute for Medical Research (BE)
- Sheba Medical Center (IL)
- Universitair Ziekenhuis Leuven (BE)
- Peter MacCallum Cancer Centre (AU)
- Amplyx Pharmaceuticals (United States) (US)
- German Center for Infection Research (DE)
- Cologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases (DE)
- University Hospital Cologne (DE)
- University of California Davis Medical Center (US)
- KU Leuven (BE)
Publication Details
- Journal
- Clinical Infectious Diseases
- Published
- 2025-04-08
- DOI
- https://doi.org/10.1093/cid/ciaf185
- Citations
- 22
- Primary Topic
- Antifungal resistance and susceptibility
- Type
- article
- Field-Weighted Citation Impact
- 30.72